Trial Profile
A Multi-center and Non-interventional Registry of BrentuximabVedotinin Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma or Classical Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma; Hodgkin's disease
- Focus Therapeutic Use
- Acronyms BRAVO
- 04 Feb 2022 Status changed from recruiting to completed.
- 23 Oct 2020 Planned End Date changed from 30 Jun 2021 to 30 Dec 2021.
- 23 Oct 2020 Planned primary completion date changed from 30 Jun 2020 to 30 Dec 2021.